In vivo treatment of tumor-bearing mice showed that doxorubicin, paclitaxel significantly increased the number of CD4+ and CD8+ T cells, which may be related to the expression of IFN-γ and granase B (Tsuda et al., 2007; Alizadeh et al., 2014; Heeren et al., 2019). Here, CD8A is linked to neoplasm.